Loading stock data…
MAZE
$27.17+0.59 (+2.22%)
Market ClosedLast close May 1
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Maze Therapeutics, Inc. in the Healthcare sector is trading at $27.17. The stock is currently 49% below its 52-week high of $53.65, remaining 15.3% below its 200-day moving average. Technical signals show neutral RSI of 49 and bullish MACD crossover, explaining why MAZE maintains its current current market pressure. The Whystock Score of 35/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 49) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$27.17
Potential Upside
5%
Whystock Fair Value$28.53
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus11 analysts
Mean target$63.55+133.9%
Range$46.00 – $110.00
Fundamentals
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibit...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.32B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-36.94%
Volume
Today's trading volume
843,596
Recent News
What Makes Maze Therapeutics (MAZE) One of the Best Oversold Small-Cap Stocks to Buy
Maze Therapeutics Inc. (NASDAQ:MAZE) is one of the 10 oversold small cap stocks to buy now. As of the April 24 closing, the consensus sentiment around the stock was strongly bullish. It received Buy ratings from all 12 analysts who provided coverage. Moreover, it offers almost 150% upside potential, based on a median 1-year price […]
Truist Updates Maze Therapeutics, Inc. (MAZE) Model for Share Count and Warrant Impact
We recently compiled a list of the 8 Oversold Biotech Stocks to Invest In Now. Maze Therapeutics, Inc. is one of the oversold stocks on our list. TheFly reported on April 14 that Truist Securities maintained its Buy rating on MAZE while reducing its price target from $68 to $64. The revision follows the company’s […]
Here is why Maze Therapeutics (MAZE) is Among the Top 8 Oversold Strong Buy-Rated Stocks
Maze Therapeutics, Inc. (NASDAQ:MAZE) is one of the 8 Most Oversold Strong Buy-Rated Stocks to Invest In. On March 31, 2026, JPMorgan raised the price target on Maze Therapeutics, Inc. (NASDAQ:MAZE) to $58 from $52 and maintained an Overweight rating. JPMorgan cited a higher probability of success for MZE829 following Phase 2 data and said […]
Maze Therapeutics' Chief Medical Officer Sold 100% of His Direct Holdings. Here's What This Means for Investors.
This clinical-stage biotech focused on precision medicines for kidney and metabolic diseases just reported a notable insider sale.
After Plunging 30.8% in 4 Weeks, Here's Why the Trend Might Reverse for Maze Therapeutics, Inc. (MAZE)
The heavy selling pressure might have exhausted for Maze Therapeutics, Inc. (MAZE) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.